SCHEMBL2477781

SCHEMBL2477781

Cc1nccn1-c1ccc(Nc2nc(CCC3CCCCC3)c3c(n2)CCN(C(=O)O)C3)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.40
CYP3A4 P08684 2/20 0.34
CYP2D6 P10635 2/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
KCNH2 Q12809 1/20 0.34
PORCN Q9H237 1/20 0.34
ROCK2 O75116 1/20 0.33
SRC P12931 2/20 0.33
JAK2 O60674 1/20 0.33
PDE10A Q9Y233 2/20 0.32
CDK4 P11802 2/20 0.32
CCND1 P24385 1/20 0.32
CCND2 P30279 1/20 0.32
CCND3 P30281 1/20 0.32
BRD4 O60885 1/20 0.32
CREBBP Q92793 1/20 0.32
GPR119 Q8TDV5 1/20 0.32
NR3C2 P08235 3/20 0.32
CDK1 P06493 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2447366 0.94 SYK (0.40) SYKCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL2451543 0.91 SYK (0.41) SYKCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL8904900 0.90 MAPT (0.44) SYKCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL2479399 0.88 SYK (0.37) SYKROCK2SRCJAK2CDK4
SCHEMBL2453366 0.88 SYK (0.36) SYKCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL2480088 0.88 SYK (0.37) SYKROCK2SRCJAK2CDK4
SCHEMBL2450514 0.85 LRRK2 (0.38) SYKCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL2446932 0.83 SYK (0.46) SYKJAK2JAK3AURKA
SCHEMBL2483361 0.83 ROCK2 (0.40) SYKCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL8904410 0.83 MAPT (0.47) SYKJAK2PDE10ACDK4CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 US disclosed
EP-2367826-A1 MODULATORS OF AMYLOID BETA. AstraZeneca AB (SE) 2011-09-28 EP disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 US disclosed
WO-2010053438-A1 MODULATORS OF AMYLOID BETA. ASTRAZENECA AB (SE) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130495-A1 COMPOUNDS 563 BACE1, PSEN1, PSEN2 SYK 641/4885CYP3A4 4727/4885CYP2D6 4725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.